2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1549

Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1472

Primary Sjögren’s Syndrome and Development of Another Connective Tissue Disease During Follow-up

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1085

Probiotic Use and Psoriatic Arthritis Disease Activity

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1056

Profibrotic Macrophage Activation in Systemic Sclerosis Is Dependent on the Mechanosensing MRTF-A Pathway

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1583

Prognostic Value of Urinary Biomarkers for the Developing of End Stage Renal Disease in Patients with Systemic Lupus Erythematosus

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1624

Progression and Factors Associated with Damage Accrual in a SLE Inception Cohort of Hispanic Patients

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1040

Proposition of a Novel Animal Model of Systemic Sclerosis Induced by Type V Collagen in C57BL/6 Mice Reproducing Fibrosis, Vasculopathy and Autoimmunity

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1055

Proteomic and Transcriptomic Analysis of Human Eosinophilic Fasciitis Fibroblasts

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1086

Psoriatic Arthritis – Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1212

Psychological Profile in Patients with Rheumatic Diseases in China: A Study of HADS Self-assessment with Smart System of Disease Management (SSDM)

Measures Of Healthcare Quality Poster II: Improving Care

9:00AM-11:00AM: Abstract Number: 1203

Psychometric Properities of the Patient Related Outcome Measure FACIT-Fatigue in Rheumatic Arthritis and Psoriatic Arthritis: A Literature Review

Measures Of Healthcare Quality Poster II: Improving Care

9:00AM-11:00AM: Abstract Number: 1461

Pulmonary Cysts: Very Common Finding on Computed Tomography of the Chest of Asymptomatic Patients with Primary Sjögren’s Syndrome

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1305

Quality Improvement in Diagnostic and Therapeutic Arthrocentesis in the Flexed Knee Using Pneumatic Compression of the Suprapatellar Bursa

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1264

Quality of Life in Patients with SAPHO Syndrome: A Single-center Survey of 588 Patients

Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

9:00AM-11:00AM: Abstract Number: 1195

Quantitative Physician Global Assessment of Damage And/or Distress, in Addition to Inflammation, at Routine Rheumatology Care: Documenting the Complexity of Rheumatology Patient Encounters as a Rationale for Possible Higher Reimbursement?

Measures Of Healthcare Quality Poster II: Improving Care

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].